Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly  Settings
FLXN Flexion Therapeutics, Inc. daily Stock Chart
FLXN [NASD]
Flexion Therapeutics, Inc.
Healthcare | Drugs - Generic | USA
financial highlights | statements
Index- P/E- EPS (ttm)-4.80 Insider Own0.60% Shs Outstand37.82M Perf Week10.12%
Market Cap551.39M Forward P/E- EPS next Y-3.83 Insider Trans8.10% Shs Float36.41M Perf Month12.07%
Income-179.60M PEG- EPS next Q-1.17 Inst Own- Short Float25.49% Perf Quarter-21.36%
Sales13.30M P/S41.46 EPS this Y-46.50% Inst Trans-0.18% Short Ratio11.97 Perf Half Y-46.40%
Book/sh3.86 P/B3.78 EPS next Y17.60% ROA-46.90% Target Price28.88 Perf Year-35.69%
Cash/sh8.01 P/C1.82 EPS next 5Y- ROE-88.20% 52W Range10.98 - 29.10 Perf YTD28.80%
Dividend- P/FCF- EPS past 5Y-32.60% ROI-30.90% 52W High-49.90% Beta1.62
Dividend %- Quick Ratio8.70 Sales past 5Y- Gross Margin60.50% 52W Low32.79% ATR0.87
Employees251 Current Ratio8.90 Sales Q/Q- Oper. Margin- RSI (14)58.45 Volatility6.95% 7.46%
OptionableYes Debt/Eq1.09 EPS Q/Q-7.80% Profit Margin- Rel Volume1.03 Prev Close14.58
ShortableYes LT Debt/Eq1.02 EarningsJan 03 AMC Payout- Avg Volume775.25K Price14.58
Recom1.90 SMA2014.19% SMA501.93% SMA200-30.53% Volume0 Change0.00%
Jan-04-19Reiterated Needham Buy $42 → $36
Jan-04-19Downgrade The Benchmark Company Buy → Hold
Jun-28-18Initiated The Benchmark Company Buy $39
Oct-09-17Reiterated Needham Buy $36 → $42
Aug-24-17Initiated Northland Capital Outperform
Dec-22-16Initiated Raymond James Strong Buy
Sep-06-16Resumed Lake Street Buy $38
Jul-21-16Initiated Lake Street Buy $38
May-03-16Resumed Wells Fargo Outperform
Nov-04-15Initiated Cantor Fitzgerald Buy
Sep-09-15Reiterated Needham Buy $31 → $28
May-14-15Initiated Northland Capital Outperform $40
Mar-31-15Initiated MLV & Co Buy $38
Aug-14-14Initiated Summer Street Research Buy $25
Mar-10-14Initiated Needham Buy $26
Jan-04-19 04:30PM  Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire +6.41%
07:59AM  The Daily Biotech Pulse: Novavax Reports Positive Influenza Vaccine Trial Data, Flexion Warns Of Revenue Shortfall, Retrophin's New CEO Benzinga
Jan-03-19 04:36PM  Flexion shares plummet after weak revenue guidance MarketWatch
04:01PM  Flexion Therapeutics Announces Preliminary, Unaudited Fourth-Quarter and Full-Year 2018 Revenue and Initial Revenue Guidance for 2019 GlobeNewswire
12:05PM  Raymond James: Flexion Therapeutics Estimates Are A Stretch Benzinga
10:26AM  Flexion Starts Phase III Enrollment on Zilretta for Hip OA Zacks
Jan-02-19 04:30PM  Flexion Therapeutics Enrolls First Patient in Phase 3 Trial of ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) in OA of the Hip and Reports Results from SHIP Study GlobeNewswire +10.07%
Dec-20-18 04:00PM  Flexion Therapeutics to Report Preliminary Unaudited 2018 Revenue and Provide 2019 Revenue Guidance on January 3, 2019 GlobeNewswire
Dec-17-18 04:30PM  Flexion Therapeutics Submits Supplemental New Drug Application (sNDA) for ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) GlobeNewswire
Dec-11-18 11:01AM  Here's Why Flexion Therapeutics Jumped 20.5% in November Motley Fool
Dec-04-18 04:30PM  Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Nov-28-18 10:07AM  2 Small Biotech Stocks That Insiders Are Buying TheStreet.com
Nov-27-18 01:53PM  Flexion Therapeutics Inc (NASDAQ:FLXN): What Does Its Beta Value Mean For Your Portfolio? Simply Wall St.
08:45AM  New Research Coverage Highlights Phibro Animal Health, RadNet, Amphastar Pharmaceuticals, FibroGen, Sientra, and Flexion Therapeutics Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Nov-16-18 09:22AM  Flexion Therapeutics Named Top Place to Work for Second Consecutive Year by The Boston Globe GlobeNewswire
Nov-08-18 09:37PM  Edited Transcript of FLXN earnings conference call or presentation 7-Nov-18 9:30pm GMT Thomson Reuters StreetEvents +19.06%
Nov-07-18 07:30PM  Flexion Therapeutics (FLXN) Reports Q3 Loss, Tops Revenue Estimates Zacks
06:34PM  Flexion Therapeutics: 3Q Earnings Snapshot Associated Press
04:01PM  Flexion Therapeutics Reports Third-Quarter 2018 Financial Results and Recent Business Highlights GlobeNewswire
Nov-05-18 06:30AM  Flexion Therapeutics Announces Product-Specific J Code (J3304) for ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) Effective January 1, 2019 GlobeNewswire
Oct-31-18 07:30AM  Flexion Therapeutics to Report Third-Quarter 2018 Financial Results on November 7, 2018 GlobeNewswire -5.45%
Oct-22-18 07:30AM  Flexion Therapeutics to Present Results from Phase 2 Trial Evaluating ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) in Bilateral Knee OA at 2018 ACR Annual Meeting GlobeNewswire -9.08%
Oct-16-18 08:45AM  Factors of Influence in 2018, Key Indicators and Opportunity within Iamgold, Mazor Robotics, Flexion Therapeutics, Hemisphere Media Group, Criteo S.A, and EP Energy New Research Emphasizes Economic Growth GlobeNewswire +6.23%
Oct-05-18 04:30PM  Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Sep-10-18 09:00AM  Flexion Therapeutics Announces Publication of Phase 2 Diabetes Data in September Issue of Rheumatology GlobeNewswire
Sep-07-18 04:30PM  Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Aug-28-18 04:30PM  Flexion Therapeutics to Present at the 2018 Wells Fargo Healthcare Conference GlobeNewswire +5.04%
Aug-20-18 05:23PM  Flexion Therapeutics Announces Presentation of Phase 3 Data at Military Health System Research Symposium GlobeNewswire
Aug-17-18 08:00AM  Report: Developing Opportunities within Adesto Technologies, BLACKLINE INC, Altice, Flexion Therapeutics, EZCORP, and CorVel Future Expectations, Projections Moving into 2018 GlobeNewswire
Aug-10-18 06:19AM  Note to Musk: Tesla isn't the only company targeted by short sellers. Here's who tops the list in Mass. American City Business Journals
Aug-07-18 06:35PM  Flexion Therapeutics (FLXN) Reports Q2 Loss, Lags Revenue Estimates Zacks
05:30PM  Flexion Therapeutics: 2Q Earnings Snapshot Associated Press
04:01PM  Flexion Therapeutics Reports Second-Quarter 2018 Financial Results and Recent Business Highlights GlobeNewswire
02:30PM  Flexion Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Aug-03-18 04:30PM  Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Jul-30-18 04:30PM  Flexion Therapeutics to Report Second-Quarter 2018 Financial Results on August 7, 2018 GlobeNewswire
Jul-25-18 07:35AM  Free Technical Research on Evolus and Three More Generic Drugs Equities ACCESSWIRE -5.97%
Jul-03-18 04:30PM  Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Jun-21-18 09:00AM  Flexion Therapeutics Named one of Boston Business Journals Best Places to Work for the Second Year in a Row GlobeNewswire
Jun-19-18 07:15AM  Free Stock Performance Review on Zoetis and Three Additional Generic Drugs Stocks ACCESSWIRE
Jun-13-18 09:00AM  Alcami's Extended Workbench Supports Commercial Supply of Flexion Therapeutics's ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) PR Newswire
Jun-01-18 05:13PM  Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
May-29-18 08:10AM  Factors of Influence in 2018, Key Indicators and Opportunity within Assembly Biosciences, MGP Ingredients, Globant S.A, 8point3 Energy Partners LP, Flexion Therapeutics, and Enanta Pharmaceuticals New Research Emphasizes Economic Growth GlobeNewswire
May-10-18 03:46AM  Edited Transcript of FLXN earnings conference call or presentation 8-May-18 8:30pm GMT Thomson Reuters StreetEvents
May-08-18 05:37PM  Flexion Therapeutics: 1Q Earnings Snapshot Associated Press
04:01PM  Flexion Therapeutics Reports First-Quarter 2018 Financial Results and Recent Business Highlights GlobeNewswire
May-07-18 07:30AM  Flexion Therapeutics Names David Arkowitz as Chief Financial Officer GlobeNewswire
May-04-18 07:30AM  Flexion Therapeutics Announces ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) Recommended for Unique J Code by CMS GlobeNewswire
May-03-18 04:30PM  Flexion Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Apr-30-18 04:30PM  Flexion Therapeutics to Report First-Quarter 2018 Financial Results on May 8, 2018 GlobeNewswire
Apr-29-18 09:00AM  Flexion Therapeutics Announces Presentation of Positive FX201 Data at the Osteoarthritis Research Society International World Congress GlobeNewswire
Apr-26-18 07:30AM  Flexion Therapeutics Presents Updated Results from Clinical Trial Evaluating Repeat Administration of ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) at Osteoarthritis Research Society International World Congress GlobeNewswire +5.52%
Apr-24-18 04:30PM  Flexion Therapeutics to Present Data on ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) at the Academy of Managed Care Pharmacy Annual Meeting 2018 GlobeNewswire
Apr-18-18 04:20PM  Flexion Therapeutics Announces Publication of Results from Pivotal Phase 3 Study of ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) in the Journal of Bone and Joint Surgery GlobeNewswire
Apr-06-18 04:30PM  Flexion Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
08:38AM  Why Flexion Therapeutics (FLXN) Could Be Positioned for a Slump Zacks
Apr-05-18 07:55AM  Detailed Research: Economic Perspectives on The Habit Restaurants, MUELLER WATER PRODUCTS, The Carlyle Group, Flexion Therapeutics, Hexcel, and Adesto Technologies What Drives Growth in Today's Competitive Landscape GlobeNewswire -5.25%
Mar-19-18 09:00AM  Flexion Therapeutics to Present at Needham & Company's 17th Annual Healthcare Conference GlobeNewswire
Mar-09-18 06:10PM  Edited Transcript of FLXN earnings conference call or presentation 8-Mar-18 9:30pm GMT Thomson Reuters StreetEvents
04:15PM  Why A Key Drug Launch Wasn't Enough To Help This Biotech Stock Investor's Business Daily
Mar-08-18 05:05PM  Flexion Therapeutics reports 4Q loss Associated Press
04:01PM  Flexion Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results GlobeNewswire
01:00PM  Flexion Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Mar-07-18 09:00AM  Flexion Therapeutics to Present at the Cowen 38th Annual Health Care Conference GlobeNewswire
Mar-06-18 07:30AM  Flexion Therapeutics Presents Clinical Data at AAOS 2018 Annual Meeting and the American Pain Society Annual Scientific Meeting GlobeNewswire
Mar-02-18 04:30PM  Flexion Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Feb-28-18 09:00AM  Flexion Therapeutics to Present at the 39th Annual Raymond James Institutional Investors Conference GlobeNewswire
Feb-26-18 04:30PM  Flexion Therapeutics to Report Fourth Quarter and Full Year 2017 Financial Results on March 8, 2018 GlobeNewswire
Feb-14-18 04:30PM  Flexion Therapeutics to Present at the RBC Capital Markets 2018 Global Healthcare Conference GlobeNewswire
Feb-08-18 07:55AM  New Research: Key Drivers of Growth for Radian Group, Flexion Therapeutics, Andeavor, Haverty Furniture Companies, Ares Capital, and Sempra Energy Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Feb-02-18 04:30PM  Flexion Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Jan-08-18 07:30AM  Flexion Therapeutics Announces Initial Data from Clinical Trial Evaluating Repeat Administration of ZILRETTA (triamcinolone acetonide extended-release injectable suspension) GlobeNewswire
Dec-29-17 09:00PM  3 Biotechs Launching Their First Commercial Drugs in 2018 Motley Fool
03:00AM  Flexion Therapeutics Getting Closer To Key Technical Measure Investor's Business Daily
Dec-18-17 04:05PM  Flexion Therapeutics Enrolls First Patient in Study Evaluating the Pharmacokinetics and Safety of ZILRETTA (triamcinolone acetonide extended-release injectable suspension) in Osteoarthritis of the Shoulder and Hip GlobeNewswire
Dec-13-17 04:05PM  Flexion Therapeutics Announces Acquisition of Novel, Non-Opioid Asset for Osteoarthritis of the Knee GlobeNewswire
Dec-11-17 04:05PM  Flexion Therapeutics Announces Appointment of Scott Kelley, M.D. as Chief Medical Officer GlobeNewswire
Dec-10-17 07:16PM  2018 Is a Critical Year for These 3 Small Commercial-Stage Biotech Stocks Motley Fool
Dec-07-17 04:35PM  Flexion Therapeutics Enrolls First Patient in Phase 2 Pharmacokinetics and Safety Study of ZILRETTA (triamcinolone acetonide extended-release injectable suspension) in Bilateral Osteoarthritis of the Knee GlobeNewswire
Dec-06-17 04:30PM  Flexion Therapeutics to Present at the BMO Capital Markets Prescriptions for Success Healthcare Conference GlobeNewswire
Dec-04-17 04:30PM  Flexion Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Nov-30-17 05:01PM  Flexion's (FLXN) Zilretta Therapy to Fast Capture OA Market Zacks
Nov-29-17 03:00AM  Stocks To Watch: Flexion Therapeutics Sees RS Rating Jump To 83 Investor's Business Daily
Nov-28-17 04:05PM  Flexion Therapeutics to Present at Evercore ISI 2017 Biopharma Catalyst/Deep Dive Conference GlobeNewswire
11:58AM  Biotech Pullback Makes Bargains Out Of Alexion, Flexion, Clovis, Tesaro And Incyte Forbes
07:14AM  This Small-Cap Biotech Stock Is Onto Something Big Motley Fool
Nov-27-17 08:00AM  Today's Research Reports on Stocks to Watch: Flexion Therapeutics and Teva Pharmaceutical ACCESSWIRE -7.03%
Nov-20-17 07:30AM  Flexion Therapeutics Announces Full Commercial Launch and Nationwide Availability of ZILRETTA (triamcinolone acetonide extended-release injectable suspension) GlobeNewswire
Nov-17-17 09:00AM  Flexion Therapeutics Named Top Place to Work for 2017 by The Boston Globe GlobeNewswire
Nov-08-17 08:41PM  Edited Transcript of FLXN earnings conference call or presentation 6-Nov-17 9:30pm GMT Thomson Reuters StreetEvents
Nov-07-17 01:23PM  Is There Now An Opportunity In Flexion Therapeutics Inc (FLXN)? Simply Wall St.
Nov-06-17 05:07PM  Flexion Therapeutics reports 3Q loss Associated Press
04:05PM  Flexion Therapeutics Reports Third-Quarter 2017 Financial Results and Recent Business Highlights GlobeNewswire
03:00AM  Flexion Therapeutics Getting Closer To Key Technical Measure Investor's Business Daily
Nov-02-17 04:05PM  Flexion Therapeutics Highlights Two Clinical Data Presentations at the 2017 American College of Rheumatology Annual Meeting GlobeNewswire
Oct-30-17 04:05PM  Flexion Therapeutics to Report Third-Quarter 2017 Financial Results on November 6, 2017 GlobeNewswire
Oct-25-17 01:18PM  Stocks on My Radar on This Selling TheStreet.com -5.68%
Oct-17-17 01:55PM  Applied Optoelectronics, Helios And Matheson Among The Top Stocks With Short Sellers Benzinga
Oct-15-17 05:00PM  Flexion's Latest FDA Approval Reignites Takeover Chatter TheStreet.com
Oct-13-17 01:15AM  A New FDA Approval Sends Small Cap Flexion Soaring Motley Fool
Flexion Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It lead product candidate includes Zilretta, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee. The company also develops FX101 and FX201, which is a pre-clinical stage programs for the treatment OA of large joints. The company was founded in 2007 and is headquartered in Burlington, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Levine Mark S.General CounselJan 03Sale12.367349,0729,060Jan 04 05:12 PM
Wentworth KerryChief Regulatory OfficerJan 03Sale12.366227,68811,207Jan 04 05:10 PM
KELLEY SCOTTChief Medical OfficerJan 03Sale12.366227,68815,271Jan 04 05:09 PM
Bodick NeilChief Scientific OfficerJan 03Sale12.367469,22164,782Jan 04 05:06 PM
Clayman Michael D.President and CEOJan 03Sale12.363,27840,51666,810Jan 04 05:03 PM
Clayman Michael D.President and CEONov 09Buy17.105,00085,47769,166Nov 13 09:17 AM
Arkowitz DavidChief Financial OfficerNov 09Buy16.564,00066,22248,250Nov 13 09:14 AM
Arkowitz DavidChief Financial OfficerAug 09Buy23.424,00093,68044,250Aug 10 12:56 PM
Clayman Michael D.President and CEOAug 09Buy22.3310,000223,30075,282Aug 10 09:13 AM
Bodick NeilChief Scientific OfficerJul 03Sale25.0016,492412,30062,307Jul 03 04:07 PM
Bodick NeilChief Scientific OfficerJul 02Sale25.1033,508841,19278,799Jul 03 04:07 PM
Bodick NeilChief Scientific OfficerMay 11Option Exercise0.1637,7026,130112,307May 11 04:07 PM
open in yahoo | open in reuters | open in google